Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Lancet

Volumn 370, Issue 9598, 2007, Pages 1543-1551

  Aponte, John J ^a,b   Aide, Pedro ^b,c   Renom, Montse ^a,b   Mandomando, Inacio ^b,c   Bassat, Quique ^a,b   Sacarlal, Jahit ^b,d   Manaca, M Nelia ^b   Lafuente, Sarah ^a   Barbosa, Arnoldo ^a,b   Leach, Amanda ^f   Lievens, Marc ^f   Vekemans, Johan ^f   Sigauque, Betuel ^b,c   Dubois, Marie Claude ^f   Demoitié, Marie Ange ^f   Sillman, Marla ^g   Savarese, Barbara ^g   McNeil, John G ^g   Macete, Eusebio ^b,e   Ballou, W Ripley ^f   Cohen, Joe ^f   Alonso, Pedro L ^a,b   more..

^a HOSPITAL CLÍNIC   (Spain)

^b Ministérioda Saúde   (Mozambique)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^e MINISTRY OF HEALTH   (Mozambique)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^g PATH Malaria Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MALARIA VACCINE; POLIOMYELITIS VACCINE; PYRIMETHAMINE; RECOMBINANT HEPATITIS B VACCINE; RTS,S/AS02D; SULFADOXINE; TETRACTHIB; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALARIA; MALE; MOZAMBIQUE; PAIN; PARASITEMIA; PERTUSSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWELLING; TETANUS;

EID: 35548999572     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61542-6     Document Type: Article

References (14)

1. Kester K., McKinney D., Tornieporth N., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 (2001) 640-647
2. Stoute J., Slaoui M., Heppner D., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (1997) 86-91
3. Bojang K., Milligan P., Pinder M., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
4. Alonso P., Sacarlal J., Aponte J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
5. Alonso P., Sacarlal J., Aponte J., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
6. Macete E., Aide P., Aponte J., et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 194 (2006) 276-285
7. Schellenberg D., Menendez C., Kahigwa E., et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357 (2001) 1471-1477
8. Hutton G., and Tediosi F. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg 75 2 Suppl (2006) 119-130
9. Alonso P., Saute F., and Aponte J. Manhiça DSS, Mozambique. In: Sankoh O., Ngom P., Nyarko P., Mwageni E., and Kahn K. (Eds). Population and health in developing countries; vol 1, population, health and survival at INDEPTH sites (2002), International development research center, Ottawa 189-195
10. Macete E., Sacarlal J., Aponte J., et al. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials 8 (2007) 11
11. Macete E., Aponte J., Guinovart C., et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 12 (2007) 37-46
12. Saute F., Aponte J., Almeda J., et al. Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhica district. Trans R Soc Trop Med Hyg 97 (2003) 661-666
13. Trape J., and Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12 (1996) 236-240
14. Diallo D., Sutherland C., Nebie I., et al. Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso. Am J Trop Med Hyg 76 (2007) 237-244